MetaCap

IRulya Therapeutics Inc. (IRLA)

NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.88-0.06 (-0.15%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRLA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$432.36M
EPS (TTM)
-$162.79
52-week range
15.10 – 910.00
Day range
38.92 – 42.00
Volume / Avg
200.56K / 63.03K
Beta
—

52-week range

$15.10$910.00

IRLA stock today

On Nov 20, IRLA ended the session at $39.88, shedding $0.06 (0.15%), versus the S&P 500's 3.70% decline. Volume was 3.2x the average at 200.56K shares, a sign of unusually heavy trading. At this level, IRLA sits near the bottom of its 52-week range of $15.10 to $910.00: 95.6% below the high and 164.1% above the low.

IRulya Therapeutics has posted a net loss over the last twelve months (EPS of -$162.79), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About IRulya Therapeutics

Company profile

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Brigette Roberts M.D.
Headquarters
New Haven, CT
Employees
38
IPO year
2019
Website
irulya.com

Financial highlights

Full financials

IRulya Therapeutics reported a net loss of $84.0 million, compared with a loss of $56.8 million a year earlier. Diluted earnings per share came in at -$1.68.

IRulya Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-83.98M$-56.83M$-31.39M$-51.66M$-89.94M
EPS (diluted)$-1.68$-1.31$-0.84$-1.54$-3.03

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$76.13+90.90%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $65.00High $98.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-1.12 vs $-0.84
Surprise
-33.33%

IRLA news

All IRLA news

IRulya Therapeutics peers

Health Care sector
IRLA peer companies
CompanyPrice% ChgMarket capCompare
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs IRLA
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs IRLA
TVGNTevogen Inc.5.90-6.35%$405.20Mvs IRLA
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs IRLA
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs IRLA
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs IRLA
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs IRLA
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs IRLA

Indexes, lists and sector

IRulya Therapeutics stock FAQ

What is IRulya Therapeutics's stock price today?

IRLA last traded at $39.88 as of Nov 20, 4:00 PM EST, down 0.15% on the day. Prices are delayed at least 15 minutes.

Who is IRulya Therapeutics's CEO?

Dr. Brigette Roberts M.D. is the chief executive officer of IRulya Therapeutics Inc., which has about 38 employees.

What is the IRLA 52-week high?

The 52-week high for IRLA is $910.00 and the 52-week low is $15.10. The stock is currently 95.6% below its high.

Compare IRLA